Research Ethics in Stopping Opioid Use Disorder Medication

This Viewpoint explores the ethical questions involved in the design and conduct of the RDD trial among individuals stopping medications for opioid use disorder.

Corresponding Author: Roger D. Weiss, MD, Division of Alcohol, Drugs and Addiction, McLean Hospital, 115 Mill St, Belmont, MA 02478 (rweiss@mclean.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.